And that is the conundrum with PAR. The product and supporting science seem wonderful but thanks to inept management and no governance, execution has been awful. This thing needs three legs to stand up. Alas two are broken.
I've no doubt iPPS will be a great medical success sometime in the future but I'm not so confident that current shareholders will get much financial benefit. Whoever comes in and picks up the pieces will be the real winner.
Sharewise Presentation 22/7/24, page-56
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.020(8.51%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 25.5¢ | 23.5¢ | $161.2K | 660.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 77422 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 15109 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |